New drug combo wows Aussie cardiologists

A new drug combination therapy for the treatment of chronic coronary or peripheral artery disease has the potential to change clinical practice, according to leading Australian cardiologists.

Presented at the  at the European Society of Cardiology (ESC) annual congress in Barcelona, Spain, this week, results from a phase III trial of 27,395 patients with stable cardiovascular disease show that a combination of the non-vitamin K oral anticoagulant rivaroxaban plus aspirin reduces the relative risk of stroke, cardiovascular death and heart attack by 24% compared with mono-dose aspirin.